Premier Inc. has submitted comments to the U.S. Food and Drug Administration (FDA) regarding the agency's new PreCheck program, which aims to accelerate the establishment of high-priority pharmaceutical manufacturing facilities in the United States and reinforce the domestic pharmaceutical supply chain. In its feedback, Premier expressed strong support for the program, emphasizing the need for increased inspections, streamlined regulatory processes, and additional incentives to boost domestic production of critical pharmaceutical products and active pharmaceutical ingredients (APIs). The company also urged the FDA to prioritize essential medicines identified by both the FDA and the Department of Defense, ensure the program covers all components of essential medicines, and expand its scope to include essential medical devices and their components.